Ceftaroline fosamil for the treatment of Gram-positive endocarditis

CAPTURE study experience

Christopher J. Destache, David J. Guervil, Keith S. Kaye

Research output: Contribution to journalArticle

Abstract

Background: The clinical experience of ceftaroline fosamil (CPT-F) therapy for Gram-positive infective endocarditis is reported from CAPTURE, a retrospective study conducted in the USA. Methods: Data, including patient demographics, medical history, risk factors, microbiological aetiology and clinical outcomes, were collected by review of patient charts between September 2013 and February 2015. Results: Patients (n=55) with Gram-positive endocarditis were treated with CPT-F. The most common risk factors were intravascular devices (43.6%), diabetes mellitus (40.0%) and injection drug use (38.2%). The most commonly isolated pathogens were meticillin-resistant Staphylococcus aureus (MRSA; 80%), meticillin-susceptible S. aureus (MSSA; 7.3%) and coagulase-negative staphylococci (7.3%). CPT-F was given as first-line therapy in 7.3% of patients and as second-line or later therapy in 92.7% of patients, and as monotherapy in 41.8% of patients and as concurrent therapy in 58.2% of patients. Clinical success was observed in 82.6% (19/23) of patients treated with CPT-F as monotherapy. In patients treated with CPT-F as first-line therapy or second-line or later therapy, 75.0% (3/4) and 70.6% (36/51) achieved success, respectively. Clinical success was observed in 77.3% (34/44) of patients with MRSA and 25% (1/4) of patients with MSSA. Two patients discontinued treatment with CPT-F due to an adverse event. Conclusions: CPT-F treatment was associated with a high rate of clinical success in patients with Gram-positive infective endocarditis, including those with risk factors and infections caused by MRSA. A high rate of clinical success was observed in patients treated with CPT-F used as first- line therapy or second-line or later therapy, or as monotherapy or in combination with other antibiotics.

Original languageEnglish (US)
JournalInternational Journal of Antimicrobial Agents
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Endocarditis
Therapeutics
Methicillin-Resistant Staphylococcus aureus
Methicillin
PPI-0903
Staphylococcus aureus
Coagulase
Staphylococcus
Diabetes Mellitus
Retrospective Studies
Demography

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

@article{e6b8531759854814bdd7ffa87b13e235,
title = "Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience",
abstract = "Background: The clinical experience of ceftaroline fosamil (CPT-F) therapy for Gram-positive infective endocarditis is reported from CAPTURE, a retrospective study conducted in the USA. Methods: Data, including patient demographics, medical history, risk factors, microbiological aetiology and clinical outcomes, were collected by review of patient charts between September 2013 and February 2015. Results: Patients (n=55) with Gram-positive endocarditis were treated with CPT-F. The most common risk factors were intravascular devices (43.6{\%}), diabetes mellitus (40.0{\%}) and injection drug use (38.2{\%}). The most commonly isolated pathogens were meticillin-resistant Staphylococcus aureus (MRSA; 80{\%}), meticillin-susceptible S. aureus (MSSA; 7.3{\%}) and coagulase-negative staphylococci (7.3{\%}). CPT-F was given as first-line therapy in 7.3{\%} of patients and as second-line or later therapy in 92.7{\%} of patients, and as monotherapy in 41.8{\%} of patients and as concurrent therapy in 58.2{\%} of patients. Clinical success was observed in 82.6{\%} (19/23) of patients treated with CPT-F as monotherapy. In patients treated with CPT-F as first-line therapy or second-line or later therapy, 75.0{\%} (3/4) and 70.6{\%} (36/51) achieved success, respectively. Clinical success was observed in 77.3{\%} (34/44) of patients with MRSA and 25{\%} (1/4) of patients with MSSA. Two patients discontinued treatment with CPT-F due to an adverse event. Conclusions: CPT-F treatment was associated with a high rate of clinical success in patients with Gram-positive infective endocarditis, including those with risk factors and infections caused by MRSA. A high rate of clinical success was observed in patients treated with CPT-F used as first- line therapy or second-line or later therapy, or as monotherapy or in combination with other antibiotics.",
author = "Destache, {Christopher J.} and Guervil, {David J.} and Kaye, {Keith S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ijantimicag.2019.01.014",
language = "English (US)",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",

}

TY - JOUR

T1 - Ceftaroline fosamil for the treatment of Gram-positive endocarditis

T2 - CAPTURE study experience

AU - Destache, Christopher J.

AU - Guervil, David J.

AU - Kaye, Keith S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The clinical experience of ceftaroline fosamil (CPT-F) therapy for Gram-positive infective endocarditis is reported from CAPTURE, a retrospective study conducted in the USA. Methods: Data, including patient demographics, medical history, risk factors, microbiological aetiology and clinical outcomes, were collected by review of patient charts between September 2013 and February 2015. Results: Patients (n=55) with Gram-positive endocarditis were treated with CPT-F. The most common risk factors were intravascular devices (43.6%), diabetes mellitus (40.0%) and injection drug use (38.2%). The most commonly isolated pathogens were meticillin-resistant Staphylococcus aureus (MRSA; 80%), meticillin-susceptible S. aureus (MSSA; 7.3%) and coagulase-negative staphylococci (7.3%). CPT-F was given as first-line therapy in 7.3% of patients and as second-line or later therapy in 92.7% of patients, and as monotherapy in 41.8% of patients and as concurrent therapy in 58.2% of patients. Clinical success was observed in 82.6% (19/23) of patients treated with CPT-F as monotherapy. In patients treated with CPT-F as first-line therapy or second-line or later therapy, 75.0% (3/4) and 70.6% (36/51) achieved success, respectively. Clinical success was observed in 77.3% (34/44) of patients with MRSA and 25% (1/4) of patients with MSSA. Two patients discontinued treatment with CPT-F due to an adverse event. Conclusions: CPT-F treatment was associated with a high rate of clinical success in patients with Gram-positive infective endocarditis, including those with risk factors and infections caused by MRSA. A high rate of clinical success was observed in patients treated with CPT-F used as first- line therapy or second-line or later therapy, or as monotherapy or in combination with other antibiotics.

AB - Background: The clinical experience of ceftaroline fosamil (CPT-F) therapy for Gram-positive infective endocarditis is reported from CAPTURE, a retrospective study conducted in the USA. Methods: Data, including patient demographics, medical history, risk factors, microbiological aetiology and clinical outcomes, were collected by review of patient charts between September 2013 and February 2015. Results: Patients (n=55) with Gram-positive endocarditis were treated with CPT-F. The most common risk factors were intravascular devices (43.6%), diabetes mellitus (40.0%) and injection drug use (38.2%). The most commonly isolated pathogens were meticillin-resistant Staphylococcus aureus (MRSA; 80%), meticillin-susceptible S. aureus (MSSA; 7.3%) and coagulase-negative staphylococci (7.3%). CPT-F was given as first-line therapy in 7.3% of patients and as second-line or later therapy in 92.7% of patients, and as monotherapy in 41.8% of patients and as concurrent therapy in 58.2% of patients. Clinical success was observed in 82.6% (19/23) of patients treated with CPT-F as monotherapy. In patients treated with CPT-F as first-line therapy or second-line or later therapy, 75.0% (3/4) and 70.6% (36/51) achieved success, respectively. Clinical success was observed in 77.3% (34/44) of patients with MRSA and 25% (1/4) of patients with MSSA. Two patients discontinued treatment with CPT-F due to an adverse event. Conclusions: CPT-F treatment was associated with a high rate of clinical success in patients with Gram-positive infective endocarditis, including those with risk factors and infections caused by MRSA. A high rate of clinical success was observed in patients treated with CPT-F used as first- line therapy or second-line or later therapy, or as monotherapy or in combination with other antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=85063427070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063427070&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2019.01.014

DO - 10.1016/j.ijantimicag.2019.01.014

M3 - Article

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

ER -